Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.56 |
| ▸ | ITGA4 | P13612 | 10/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | YARS1 | P54577 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL3100805 | 1.00 | SLC7A5 (0.56) | SLC7A5ITGA4ITGB1PTGS1ALPI | |
| Tyrosine SCHEMBL1675510 | 1.00 | SLC7A5 (0.56) | SLC7A5ITGA4ITGB1PTGS1ALPI | |
| Tyrosine SCHEMBL5576441 | 0.97 | SLC7A5 (0.52) | SLC7A5ITGA4ITGB1PTGS1ALPI | |
| Tyrosine SCHEMBL4352800 | 0.95 | SLC7A5 (0.61) | SLC7A5ITGA4ITGB1PTGS1ALPI | |
| Tyrosine SCHEMBL5152642 | 0.95 | SLC7A5 (0.61) | SLC7A5ITGA4ITGB1PTGS1ALPI | |
| Tyrosine SCHEMBL4205059 | 0.95 | SLC7A5 (0.61) | SLC7A5ITGA4ITGB1PTGS1ALPI | |
| Tyrosine SCHEMBL4205061 | 0.95 | SLC7A5 (0.61) | SLC7A5ITGA4ITGB1PTGS1ALPI | |
| Tyrosine SCHEMBL4612310 | 0.93 | SLC7A5 (0.48) | SLC7A5ITGA4ITGB1PTGS1ALPI | |
| Tyrosine SCHEMBL28626712 | 0.93 | SLC7A5 (0.48) | SLC7A5ITGA4ITGB1PTGS1ALPI | |
| Tyrosine SCHEMBL27683457 | 0.93 | SLC7A5 (0.48) | SLC7A5ITGA4ITGB1PTGS1ALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659118-A | Tripeptide capable of promoting HaCaT cell proliferation and application thereof | 珀莱雅化妆品股份有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-116063505-B | Anti-GAL 3 antibodies and uses thereof | 真和制药有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4352105-A2 | ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCE | TrueBinding, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117897406-A | anti-GAL 3 antibodies and methods for their use in insulin resistance | 真和制药有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117659118-A | Tripeptide capable of promoting HaCaT cell proliferation and application thereof | 珀莱雅化妆品股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117659118-A | Tripeptide capable of promoting HaCaT cell proliferation and application thereof | 珀莱雅化妆品股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230279120-A1 | METHODS OF TREATING OR INHIBITING CARDIOVASCULAR DISEASES | TRUEBINDING, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230225952-A1 | ADDITIVES FOR COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. | 2023-07-20 | — | — | US | disclosed |
| CN-116157151-A | Methods of treating inflammatory diseases by blocking galectin-3 | 真和制药有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116063520-A | anti-GAL 3 antibodies and uses thereof | 真和制药有限公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-3918323-A2 | ANTI-GAL3 ANTIBODIES AND USES THEREOF | TrueBinding, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210371533-A1 | METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKING GALECTIN-3 | TRUEBINDING, INC. | 2021-12-02 | — | — | US | disclosed |
| WO-2021242776-A2 | METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKING GALECTIN-3 | TRUEBINDING, INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| CN-113711036-A | anti-GAL 3 antibodies and uses thereof | 真和制药有限公司 | 2021-11-26 | — | — | CN | disclosed |
| WO-2021146218-A1 | ANTI-GAL3 ANTIBODIES AND METHODS OF USE | TRUEBINDING, INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021113527-A1 | ANTIBODIES THAT DISRUPT THE INTERACTION OF GAL3 AND INSULIN RECEPTOR OR INTEGRINS AND METHODS OF USE THEREOF | TRUEBINDING, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2020264257-A1 | ADDITIVES FOR COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020160156-A2 | ANTI-GAL3 ANTIBODIES AND USES THEREOF | IMMUTICS, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| CN-110066334-B | anti-Galectin-3 fully-humanized single-domain antibody and application thereof | 南京医科大学 | 2020-03-10 | — | — | CN | disclosed |
| CN-110066334-A | The full humanization single domain antibody of anti-Galectin-3 and application | 南京医科大学 | 2019-07-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230225952-A1 | ADDITIVES FOR COLORING AGENTS AND METHODS OF USE THEREOF | COXFA4L2, TYR, OAT | SLC7A5 3699/4885ITGA4 1919/4885ITGB1 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.